All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

  TRANSLATE

The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The PsOPsA Hub
Brought to you by Scientific Education Support

The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

EULAR 2025: What’s hot in psoriasis and psoriatic arthritis?

By Ella Dixon

Share:

Featured:

Ulrich MrowietzUlrich MrowietzLaura CoatesLaura CoatesAlice GottliebAlice GottliebPaolo GisondiPaolo GisondiPeter NashPeter NashYukari OkuboYukari OkuboAndré CarvalhoAndré CarvalhoJoseph MerolaJoseph Merola

Jun 9, 2025

To help navigate the exciting content being presented at the European Alliance of Associations for Rheumatology Congress (EULAR 2025), we have provided recommendations for the top abstracts to look out for in psoriasis and psoriatic arthritis.

EULAR 2025: Top abstracts in psoriasis and psoriatic arthritis

Oral abstracts

Abstract #TitleDatePresenter
OP0089Early intensive therapy with combination csDMARDs or TNF inhibitors are superior to standard step up care for the treatment of moderate to severe psoriatic arthritis: The 3-arm parallel group SPEED RCTWednesday, June 11Laura Coates
OP0094Biological sex-related differences in radiographic progression and relationship with early clinical response: Post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study in biologic-naive participants with active psoriatic arthritis treated with guselkumabWednesday, June 11Dafna D. Gladman
OP0096Impact of sonelokimab, a novel IL-17A- and IL-17F-inhibiting Nanobody, on multidomain clinical outcomes in active psoriatic arthritis: Results from the randomized, double-blind, placebo-controlled Phase 2 ARGO trialWednesday, June 11Iain Mc‎Innes
OP0106Long term outcomes of methotrexate and leflunomide combination therapy compared to methotrexate monotherapy in psoriatic arthritis: A follow-up study of the COMPLETE PsA trialWednesday, June 11Amy Peeters
OP0175Establishing definitions for difficult-to-treat psoriatic arthritis (D2T-PSA) and complex-to-manage psoriatic arthritis (C2M-PSA): Insights from the group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA) initiativeThursday, June 12Fabian Proft
LB0001Efficacy and safety of deucravacitinib up to week 16 from POETYK PsA-1: A multicenter, randomized, double-blind, placebo-controlled, phase 3 study in patients with active psoriatic arthritisSaturday, June 14Désirée van der Heijde 
LB0010Inhibition of structural damage progression with guselkumab, a selective IL-23i, in participants with active PsA: Results through Week 24 of the phase 3b, randomized, double-blind, placebo-controlled APEX studySaturday, June 14Philip J. Mease

 

Posters

Poster #Title
POS0496Deucravacitinib in moderate to severe plaque psoriasis: 5-year, long-term safety and efficacy results from the phase 3 POETYK PSO-1, PSO-2, and LTE trials
POS0574Sustained effectiveness of secukinumab in controlling disease activity in patients with psoriatic arthritis: 5-year results from SERENA
POS0816VISIBLE: Guselkumab impact on psoriatic arthritis at Week 16 in participants with moderate to severe psoriasis across all skin tones
POS1038High prevalence of inflammatory PsA-specific findings in patients with long-standing psoriasis but no musculoskeletal symptoms
POS1072Icotrokinra, a targeted oral peptide that selectively blocks the interleukin-23-receptor, for the treatment of moderate-to-severe plaque psoriasis: Results through Week 24 of the phase 3, randomized, double-blind, placebo-controlled ICONIC-LEAD trial
POS1228Cardiovascular and mortality outcomes in psoriatic arthritis patients treated with hydroxychloroquine: A 10-year retrospective analysis
POS1269EULAR Points to consider for the definitions of difficult-to-manage and treatment-refractory psoriatic arthritis
POS1280Real-world switching patterns for patients with psoriatic arthritis on first-line advanced therapies
POS1314 Icotrokinra, a novel targeted oral peptide, in patients with psoriatic disease: Exploratory assessments from a Phase 2 psoriasis study informing a Phase 3 clinical program in psoriatic arthritis
POS1329Secukinumab demonstrates high long-term efficacy, drug survival, and osteoprotective effects in psoriatic arthritis and psoriasis: 48-month follow-up of the PSARTROS study

 

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EULAR 2025PsoriasisPsoriatic arthritis

Related articles

Upcoming congress abstracts: What’s hot in psoriasis and psoriatic arthritis?

Upcoming congress abstracts: What’s hot in psoriasis and psoriatic arthritis?

To help navigate the exciting content being presented at an upcoming rheumatology congress in Washington, D.C., the PsOPsA Hub Steeri...

Nov 6, 2024

Newsletter

Subscribe to get the best content delivered to your inbox